Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Larimar TherapeuticsLRMR +0.60%35 EV-to-OCF is -1.80 as of Aug. 23, 2026. GuruFocus rates LRMR with a GF Score™ of 35/100. The stock has 2 warning signs investors should review. Among 1,409 Biotechnology companies, Larimar Therapeutics ranks worse than 60.11% on this metric.
EV-to-OCF is calculated as enterprise value divided by its cash flow from operations. As of today, Larimar Therapeutics's Enterprise Value is $280.84 Mil.
Larimar Therapeutics's Cash Flow from Operations for the trailing twelve months (TTM) ended in Jun. 2026 was $-155.92 Mil. Therefore, Larimar Therapeutics's EV-to-OCF for today is -1.80.
The historical rank and industry rank for Larimar Therapeutics's EV-to-OCF or its related term are showing as below:
LRMR'
s EV-to-OCF Range Over the Past 10 Years
Min: -1.8 Med: 0 Max: -1.8
Current: -1.8
During the past 7 years, the highest EV-to-OCF of Larimar Therapeutics was -1.80. The lowest was -1.80. And the median was .
LRMR's EV-to-OCF is ranked worse than 60.11% of 1409
companies
in the Biotechnology industry
Industry Median: -3.68
vs LRMR: -1.80
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Larimar Therapeutics's PE Ratio (TTM) for today is calculated as:
Larimar Therapeutics's share price for today is $4.16.
Larimar Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.950.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Larimar Therapeutics EV-to-OCF Related Terms
Larimar Therapeutics EV-to-OCF Historical Data
* Premium members only.
The historical data trend for Larimar Therapeutics's EV-to-OCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Larimar Therapeutics's EV-to-OCF, along with its competitors' market caps and EV-to-OCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Larimar Therapeutics EV-to-OCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Larimar Therapeutics's EV-to-OCF distribution charts can be found below:
* The bar in red indicates where Larimar Therapeutics's EV-to-OCF falls into.
Larimar Therapeutics's current Enterprise Value is $280.84 Mil.
Larimar Therapeutics's Cash Flow from Operations for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-155.92 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Larimar Therapeutics (LRMR) has a EV-to-OCF of -1.80 as of Aug. 23, 2026. According to the industry distribution chart, Larimar Therapeutics ranks #847 out of 1409 companies in the Biotechnology industry, placing it in the top 60.1%.
Is Larimar Therapeutics' EV-to-OCF too high?
Larimar Therapeutics' current EV-to-OCF is -1.80. Based on the distribution chart, Larimar Therapeutics ranks #847 out of 1409 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Larimar Therapeutics has a GF Score™ of 35/100, reflecting its overall financial health beyond just this single metric.
How does Larimar Therapeutics' EV-to-OCF compare to OCGN and EVMN?
According to the Biotechnology industry distribution chart, Larimar Therapeutics ranks #847 out of 1409 companies for EV-to-OCF. This places Larimar Therapeutics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-OCF for a Biotechnology company?
A good EV-to-OCF depends on the Biotechnology industry context. However, EV-to-OCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-OCF mean?
A high EV-to-OCF can signal that a stock is expensive relative to its fundamentals. Larimar Therapeutics's current EV-to-OCF is -1.80. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Larimar Therapeutics stock overvalued right now?
Larimar Therapeutics (LRMR) has a current EV-to-OCF of -1.80. The current EV-to-OCF is -1.80. Larimar Therapeutics' overall GF Score™ is 35/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-OCF calculated?
EV-to-OCF is calculated from a company's financial statements. For Larimar Therapeutics (LRMR), the current EV-to-OCF is -1.80 as of Aug. 23, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Larimar Therapeutics Inc is a clinical-stage biotechnology company focused on developing treatments for patients suffering from complex rare diseases using its novel cell penetrating peptide technology platform. Its flagship product candidate, nomlabofusp, is a subcutaneously administered recombinant fusion protein designed to deliver frataxin (FXN) to the mitochondria of patients with Friedreich's ataxia (FA), a rare genetic disease characterized by insufficient production of FXN. The company also plans to use its intracellular delivery platform to design other fusion proteins to target additional rare diseases characterized by deficiencies in intracellular bioactive compounds.
35GF Score
Get the complete analysis for LRMR
EV-to-OCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LRMR has been successfully added to your 
